Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

AIDS

Volumn 13, Issue 2, 1999, Pages

  Tebas, Pablo ^a,e   Patick, Amy K ^b   Kane, Ellen M ^c   Klebert, Michael K ^a   Simpson, Janet H ^c   Erice, Alejo ^c   Powderly, William G ^a   Henry, Keith ^c,d  

^a WASHINGTON UNIVERSITY   (United States)

^b AGOURON PHARMACEUTICALS INC   (United States)

^c REGIONS HOSPITAL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral failure; Antiretroviral resistance; Clinical trial; Genotype; Nelfinavir; Ritonavir; Saquinavir

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS GENE; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; NELFINAVIR; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SAQUINAVIR; TREATMENT FAILURE; VIRAL LOAD;

EID: 0033010748     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902040-00002     Document Type: Article

References (29)

1. Hammer SM, Squires KF, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study investigators. N Engl J Med 1998, 338:853-860.
3. Centers for Disease Control and Prevention: Update: trends in AIDS incidence - United States, 1996. MMWR 1997, 46:861-867.
4. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1998, 280:70-86.
5. Department of Health and Human Services and Henry J. Kaiser Family Foundation: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998, 47 (RR-5):43-82.
6. Center for Disease Control and Prevention: Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998, 47 (RR-4):1-43.
7. Centers for Disease Control and Prevention: Report of the NIH Panel to Define Principles of Therapy of HIV Infection. MMWR 1998, 47(RR-5):1 41.
8. Powderly W, Sension M, Conant M, Stein A, Clendeninn N: The efficacy of Viracept (nelfinavir mesylate) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 370].
9. Saag M, Gerstein M, Chang Y, Greenberg SI, Yu G, Clendeninn NJ: Long term virological and immunological effect of the HIV protease inhibitor, Viracept (nelfinavir mesylate, NFV) in combination with zidovudine (AZT) and lamivudine (3TC). 35th Annual Meeting of the Infectious Diseases Society of America. San Francisco, September 1997 [abstract 313].
10. Flexner C: HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1292.
11. Markowitz M, Conant M, Hurley A, et al.: A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998, 177:1533-1540.
12. Condra JH: Resisting resistance: maximizing the durability of antiretroviral therapy. Ann Intern Med 1998, 128:951-954.
13. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
14. Lawrence J, Schapiro J, Winters M, et al.: Salvage therapy with indinavir plus nevirapine in patients previously treated with two other protease inhibitors and multiple reverse transcriptase inhibitors. Fifth Conference of Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 422].
15. Cassano P, Hermans P, Sommereijns B, et al.: Combined quadruple therapy with ritonavir-saquinavir (RTV-SQV) + nucleosides in patients who failed in triple therapy with RTV, SQV or indinavir (IDV). Fifth Conference of Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 423].
16. Gerard M, De Wit S, Sprecher S, et al.: Salvage anti HIV triple therapy with foscarnet in combination with nelfinavir and nevirapine in heavily pretreated patients. Fifth Conference of Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 424].
17. De Truchis P, Force G, Zucman D, et al.: Effects of a 'salvage' combination therapy with ritonavir + saquinavir in HIV-infected patients previously treated with protease-inhibitors. Fifth Conference of Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 425].
18. Workman C, Mussen R, Sullivan J: Salvage therapy using six drugs in heavily pretreated patients. Fifth Conference of Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 426].
19. Gallant JE, Hall C, Barnett S, Raines C: Ritonavir/saquinavir (RTV/SQV) as salvage therapy after failure of initial protease inhibitor (PI) regimen. Fifth Conference of Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 427].
20. Beach RS, Wohlfeiler MB, Silva A: Indinavir (IND)/nevirapine (NVP) combination therapy in advanced HIV-1 infection. Fifth Conference of Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 428].
21. Patick AK, Mo H, Markowitz M, et al.: Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996, 40:292-297.
22. Patick AK, Duran M, Cao Y, et al.: Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998, 42:2637-2644.
23. Myers G, Wain-Hobson S, Henderson LE, Korber B, Jeang KT, Pavlakis GN: Human Retroviruses and AIDS. Los Alamos: Los Alamos National Laboratory; 1993.
24. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
25. Hertogs K, Mellors J, Schel P, et al.: Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates. Fifth Conference of Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 395].
26. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S: Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998, 12:F97-F102.
27. Para M, Coombs R, Collier A, et al.: Relationship of baseline genotype to RNA response in ACTG 333 after switching from long term saquinavir (SQVhc) to indinavir (IDV) or saquinavir soft gelatin capsule (SQVsgc). Fifth Conference of Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 511].
28. Patick AK, Zhang M, Hertogs K, et al.: Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 57].
29. Zolopa AR, Shafer RW, Warford A, Montoya JG, Katzenstein D, Merigan TC: Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 54].